STRATA Skin Sciences, Inc. announced that the first six patients have been treated in the TheraClear®?X open label, single-arm, clinical research study led by Glynis Ablon, MD, FAAD. The purpose of the study titled, "A 7-Week, Open Label, Study Evaluating the Efficacy and Safety of TheraClearX on Mitigating Mild to moderate Acne in Healthy Teenagers and Young Adults," is to further substantiate the efficacy and safety of TheraClearX as a stand-alone treatment in the mitigation of mild to moderate acne in 30 healthy male and female subjects, 12-40 years of age and older over the course of 7 weeks. The study is being conducted at the Ablon Skin Institute and Research Center in Manhattan Beach, California.

Acne is the most common skin disease in the United States affecting up to 50 million Americans annually. Research shows that 20-25% of all visits to dermatologists are for acne, and the majority of the cases are for those who suffer from a mild to moderate version. Acne is also prevalent in adolescents with 85% experiencing some degree from the ages of 12 to 24 years.

TheraClearX's FDA-cleared technology addresses the estimated $5.5 billion acne treatment market with a non-pharmaceutical, in-office procedure.